for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Markets News

Pfizer third-quarter sales fall 4.3% on pain drug weakness

Oct 27 (Reuters) - Pfizer Inc on Tuesday reported a 4.3% drop in third-quarter sales, hurt by increased competition for its off-patent pain drug Lyrica and lower demand for some of its treatments during the COVID-19 pandemic.

Sales fell to $12.13 billion from $12.68 billion a year ago.

Reporting by Manas Mishra in Bengaluru; Editing by Bernard Orr

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up